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Complications arising from Preterm Birth are the leading causes of neonatal death
globally. Current therapeutic strategies to prevent Preterm Birth are yet to demonstrate
success in terms of reducing this neonatal disease burden. Upregulation of intracellular
inflammatory pathways in uterine cells, including those involving nuclear factor kappa-B
(NFκB), have been causally linked to both human term and preterm labor, but the
barrier presented by the cell membrane presents an obstacle to interventions aimed
at dampening these inflammatory responses. Cell penetrating peptides (CPPs) are novel
vectors that can traverse cell membranes without the need for recognition by cell surface
receptors and offer the ability to deliver therapeutic cargo internal to cell membranes.
Using a human uterine cell culture inflammatory model, this study aimed to test the
effectiveness of CPP-cargo delivery to inhibit inflammatory responses, comparing this
effect with a small molecule inhibitor (Sc514) that has a similar intracellular target of
action within the NFκB pathway (the IKK complex). The CPP Penetratin, conjugated
to rhodamine, was able to enter uterine cells within a 60min timeframe as assessed
by live confocal microscopy, this phenomena was not observed with the use of a
rhodamine-conjugated inert control peptide (GC(GS)4). Penetratin CPP conjugated to an
IKK-inhibitory peptide (Pen-NBD) demonstrated ability to inhibit both the IL1β-induced
expression of the inflammatory protein COX2 and dampen the expression of a bespoke
array of inflammatory genes. Truncation of the CPP vector rendered the CPP-cargo
conjugate much less effective, demonstrating the importance of careful vector selection.
The small molecule inhibitor Sc514 also demonstrated ability to inhibit COX2 protein
responses and a broad down-regulatory effect on uterine cell inflammatory gene
expression. These results support the further exploration of either CPP-based or small
molecular treatment strategies to dampen gestational cell inflammatory responses in the
context of preterm birth. The work underlines both the importance of careful selection of
CPP vector-cargo combinations and basic testing over a broad time and concentration
range to ensure effective responses. Further work should demonstrate the effectiveness
of CPP-linked cargos to dampen alternative pathways of inflammation linked to Preterm
Birth such as MAP Kinase or AP1.
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INTRODUCTION
Preterm birth, or birth before 37 weeks completed gestation as
defined by the World Health Organization, is the main cause of
neonatal death in developed countries and presents an enormous
global problem (1). Being born too soon can confer significant
clinical deficits throughout life, leading to neuro-developmental
disorders such as cerebral palsy, learning impairment and visual
disorders; with such problems being more likely to occur with
greater frequency and severity at earlier gestations of birth (2).
Preterm birth is a syndrome best understood as the final
endpoint of several possible pathophysiological events. It can
be initiated by an array of processes including: uterine over-
distension, utero-placental hemorrhage or ischaemia, maternal
stress, cervical insufficiency, and inflammation with or without
clinically apparent infection (3). Parallel to this, there is evidence
to suggest that the processes that drive spontaneous human
labor, whether at term or preterm, have an inflammatory basis.
Macrophage and neutrophil numbers in human fetal membranes,
myometrium and cervix are increased in tissue derived from
laboring patients (4, 5) and such invasion leads to increases in
local cytokine and chemokine production including increases
in IL1β, IL8, and TNFα (6). These changes may precipitate,
or contribute to, a sequence of uterine activation processes
leading to labor (7). Furthermore, invasion of the decidua
by these cell types occurs in animal models of preterm birth
and precedes the onset of labor (8); although whether this
invasion is a cause or consequence of labor remains to be
fully defined (9). The inflammatory milieu provoked within
the uterine environment has been reported to upregulate
varied pro-inflammatory pathways in uterine and placental
cells including signaling pathways involving p38 MAP kinase
(p38 MAPK) and Activator Protein 1 (AP1) (10, 11). Most
importantly, upregulation of intracellular pathways involving the
transcription factor nuclear factor κB (NFκB) are suggested to
play a central role in the sequelae of inflammation-associated
preterm birth (12).
NFκB proteins are a family of five structurally related
transcription factors named p65 (Rel A), RelB, c-Rel, p50 (NFκB-
1), and p52 (NFκB-2) present in nearly all mammalian cells that
play a ubiquitous role in inflammatory and infectious responses
(13). All NFκB proteins exist in the form of heterogeneous
dimers, the most commonly described of which is p65/p50 which
is known to activate the expression of pro-inflammatory genes
within the uterus (14). Within the canonical NFκB pathway
interaction between cell surface receptors and lipopolysaccharide
(LPS), or pro-inflammatory cytokines such as IL-1β, TNFα,
or IL6 activates the IkB kinase complex (IKK complex) (13).
This kinase complex consists of two catalytic subunits (IKKα
& IKKβ) each containing a six amino acid segment LDWSWL,
known as the Nemo Binding Domain (NBD), which forms the
basis of their binding site with the regulatory NFκB essential
modulator (NEMO) scaffold protein. Activation of IKK leads
to the targeted phosphorylation of IkBα allowing for the
ubiquitination and subsequent degradation of this anchoring
protein by the proteasome. This step allows it to translocate to
the nucleus of the cell, a process enhanced by the IKK-dependent
phosphorylation of p65. Once in the cell nucleus, NFκB binds to
target gene promoters regulating the expression of inflammatory
genes including those that transcribe IL1β, TNFα, IL6, IL8,
CXCL2, MMP 9, and COX2 (15). Due to the presence of κB
binding sites on the IκBα gene promoter, activation of NFκB leads
to the rapid resynthesis of IκBα which dissociates NFκB from
DNA complexes and is shuttled out of the nucleus in an inactive
complex (16).
Amongst the evidence supporting the role of NFκB activation
in labor are observations from in vitro studies on human
myometriaI cells: activation of NFκB has been shown to promote
the expression of the inducible prostaglandin synthase enzyme
cyclooxygenase 2 (COX2) leading to subsequent increases in
prostaglandin production in these cells (17). Prostaglandins
E2 and F2α promote uterine contractions and their increased
production within reproductive tissues is associated with the
onset of human labor (18), thus increases in COX2 expression
are thought to correspond to both inflammatory and contractile
responses in the myometrium during human labor.
Myometrial cell NFκB activation also promotes the increased
production of pro-inflammatory cytokines including IL-6 and
IL-8 (19), matrix metalloproteinases (20), and up-regulates the
expression of mRNA encoding genes associated with labor
including the oxytocin receptor and gap junction proteins (21,
22).
Agents aimed at the acute prevention of preterm birth are a
class of drugs referred to as tocolytics. Despite their use in more
than 3000 clinical trials over 60 years, tocolytic agents have yet
to demonstrate significant improvements in neonatal outcome
and their use is frequently associated with an unacceptably high
frequency of unwanted sequelae (23). This leaves an urgent
need for the exploration of new therapeutic strategies aimed at
targeting the molecular pathways whose upregulation is linked to
preterm birth.
Peptides targeting protein-protein interactions that regulate
cellular processes are gaining increasing traction as therapeutic
entities that target a number of diseases. As biological molecules
they offer very high selectivity and specificity and are relatively
cheap to manufacture (24) A major barrier to the development
of new peptides as pharmaceuticals is presented by the cell
membrane: the lipid bilayer can prevent the passage of
therapeutics from extracellular space to intracellular targets that
often lie within the cytosol of a cell. To overcome this obstacle
requires a vector system that can deliver cargo to the cell
cytosol either directly through the plasma membrane or through
utilizing endocytosis as a portal to cytoplasm before mediating
endocytic escape processes to reach the cytosol (25).
Cell Penetrating Peptides (CPPs) offer an attractive solution to
this drug delivery puzzle: they are characterized as short peptides,
usually <30 amino acids length, that have the ability to cross
cell membranes without the need for recognition by cell surface
receptors (26). CPPs have been shown to deliver cargo efficiently
at low doses to a diverse range of cell types and a number of
studies in varied clinical fields have confirmed the potential of
CPP-cargo conjugates as therapeutic agents (27). This has led to
several CPP-based therapies being tested in phase 3 clinical trials
for a diverse range of inflammatory conditions (28). Despite this,
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the effectiveness of CPP-linked therapy in gestational cells has yet
to be examined in detail.
Amongst the broad array of cargoes that can be conjugated
to CPPs and delivered intracellularly are molecules with the
capability to block NFκB-dependent signaling (15). The best
described CPP-cargo conjugate with NFκB inhibitory ability
is the Nemo Binding Domain (NBD) peptide: an 11 amino
acid residue peptide which was designed to span the NBD and
therefore disrupt the interaction between the three IKK subunits
within the NFκB canonical pathway, with the effect of inhibiting
the inflammatory ligand-dependant activation of NFκB (29). The
NBD peptide, conjugated to varied CPP vectors, has been shown
to down-regulate elicited NFκB responses and thus improve
physiological endpoints of inflammation both in vitro and in
animal models of diseases as varied as Muscular Dystrophy and
Parkinson’s disease (30–32).
Small molecule inhibitors targeting several levels of the
NFκB pathway have been reported including those blocking
the phosphorylation of IkBα via IKK complex inhibition
or preventing proteasome degradation of this molecule
(33). Inhibitors have also been demonstrated that prevent
NFκB localization to the nucleus or block post translational
modifications of p65. The advantages of using small molecule
drug inhibition include low immunogenicity and the possibility
of attaining high oral bioavailability with the aim of inhibiting
specific signaling pathways. However, high concentrations may
be required to achieve therapeutic benefit; they may be poor at
crossing biological barriers, and are often substrates for swift
removal via drug eﬄux proteins (34).
The non-peptidic inhibitor Sc514 represents an established
small molecule compound targeting NFκB mediated effects. It
exerts action via inhibition of the IKKβ portion of the IKK
complex and therefore putatively offers discrete inhibition of the
NFκB pathway via a mechanism similar to the NBD peptide (35).
It has demonstrated ability to significantly reduce LPS-stimulated
TNFα secretion in placentally-derived human primary cells (36),
however it has yet to be broadly tested in a uterine cell setting.
Thus, the use of this drug allows examination of the efficacy of
a small molecule approach to inhibit NFκB-related inflammatory
responses in myometrial cells, as well as offering a comparison
with the CPP-cargo inhibitory approach presented by the NBD
peptide.
With the intention of broadening the scope of anti-
inflammatory candidate agents available to be tested for their
potential as treatments for preterm birth, the aims of this study
were to: (i) first define the ability of CPPs to enter human
myometrial cells and deliver the NBD peptide and (ii) subsequent
to this, examine the effectiveness of CPP-NBD peptide conjugates
in dampening NFκB related signaling compared to Sc514 in
human myometrial cells.
MATERIALS AND METHODS
Subjects & Samples
Ethical approval was obtained from Newcastle and North
Tyneside Research Ethics Committee (10/H0906/71) to perform
research on samples collected as part of the Newcastle Utero-
placental Tissue Bank. Human myometrial tissue was obtained
from patients following written informed consent from non-
laboring women with uncomplicated, singleton pregnancies
undergoing elective Cesarean section at term (≥37 weeks
gestation). Myometrial muscle strip biopsies approximately 1 ×
1 cm in size were taken from the upper portion of the lower
segment uterine incision and placed in tissue collection buffer.
Biopsies were excluded from women with underlying medical
or obstetric disease, women on any current medication, those
with a body mass index outside range 20–35 kg/m2, or who gave
birth to a baby with weight below the 10th percentile or above the
90th percentile. Separate myometrial biopsies from 46 patients
were included in the study.
Preparation of Myometrial Cells
Human myometrial biopsies were micro-dissected under a light
microscope to isolate myometrial tissue from any remaining
decidua. In a microbiological safety cabinet, tissue was cut into
small fragments before adding 10 mls warmed hanks balanced
salt solution containing 10mg each of collagenase 1A and XI
(SigmaAldrich, C7657, C9891) plus 20mg bovine serum albumin
(Sigma Aldrich, A6003). This tissue digestion mix was placed in
an orbital shaker at 110 rpm for approximately 40min at 37◦C.
The sample was then triturated, filtered through a 70µm cell
strainer into 10ml warmed media and centrifuged at 1,000 rpm
(89× g) for 5min. The supernatant was discarded and cell pellet
re-suspended in GlutaMAX cell culture media (Life Technologies
61965) containing 10% FCS and Penicillin/Streptomycin until
80–90% confluent (37).
Cell Penetrating Peptides
CPP’s were custom synthesized commercially and purchased
from either EZ Biolabs (USA) or Abingdon Health Laboratory
(UK) services. Rhodamine fluorophore cargo (excitation 561 nm,
emission 617 nm) was labeled at the N-terminal end of either
Penetratin or Pen(43-56) CPP. NBD or inactive NBD mutant
cargo was conjugated at the C-terminal end of either Penetratin
or Pen(43-56) CPP. Aminohexanoic acid (Aca) was used as a
linker between CPP and cargo. The amino acid structures of the
peptides used in experimentation are detailed in Table 1.
To test specificity of COX2 responses to the NBD peptide,
the effect of a Penetratin-conjugated mutant version of the NBD
peptide: Pen NBD (Mut), was examined. This peptide contains
the substitution of two tryptophan (W) amino acid residues
to alanine (A) thus rendering it unable to span the NBD and
interfere with IKK related signaling toward NFκB (29).
To further investigate the importance of CPP vector structure
for the delivery of biologically active cargo a truncated form of
Penetratin CPP was conjugated to the NBD peptide: Pen(43-56)-
NBD (38).
Live Cell Confocal Microscopy
Primary humanmyometrial cells at passage P≤4 were transferred
into 4 or 8-well microscope Ibidi µ-Slides (Thistle Scientific, IB-
80441, IB-80821) and grown up to 80–90% confluency. Cells
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TABLE 1 | The nomenclature and amino acid structure of peptides used for
experimentation.
Peptide name Structure
Rhodamine labeled
Penetratin
Rhodamine–RQIKIWFQNRRMKWKK
Rhodamine labeled
Pen-NBD
Rhodamine-RQIKIWFQNRRMKWKKTALDWSWLQTE
Rhodamine labeled
Pen(43-56) – NBD
Rhodamine-RQIKIWFQNRRMKW-Aca- TALDWSWLQTE
Rhodamine labeled
GS4(GC)
Rhodamine - GSGSGSGSGC
Pen-NBD RQIKIWFQNRRMKWKKTALDWSWLQTE-NH2
Pen-NBD Mutant RQIKIWFQNRRMKWKKTALDASALQTE-NH2
NBD TALDWSWLQTE
Pen (43-56)-NBD Ac-RQIKIWFQNRRMKW-Aca-TALDWSWLQTE-NH2
Pen (43-56)-NBD
Mutant
Ac-RQIKIWFQNRRMKW-Aca-TALDASALOTE-NH2
Rhodamine fluorophore cargo (excitation 561 nm, emission 617 nm) is labeled at the N-
terminal end of Penetratin or Pen(43-56) CPP. NBD or inactive NBD mutant cargo is
conjugated at the C-terminal end. Acyl (Ac), Aminohexanoic acid (Aca), Amide (NH2).
were washed in phosphate buffered saline and changed to serum-
reduced media (0.1%FCS) for 18–24 h (39). Cells were then
loaded with 1µM Hoechst nuclear dye (Life Technologies,
33342) for 1 h and washed with PBS before transfer to the
confocal microscope where they were maintained within a
temperature-controlled chamber maintained at 37◦C, 5%CO2 on
the stage of the inverted microscope.
Initial images were collected to assess baseline cellular auto-
fluorescence prior to the addition of varying concentrations of
fluorophore-CPP/fluorophore- CPP-Cargo/fluorophore-control
peptide combinations (see Table 1) that were ready made up in
serum-reduced cell media. Further images were captured 60min
following application. During imaging cells were placed in phenol
red free Dulbecco modified eagle medium (Life Technologies,
21063) to reduce background glare.
To make a thorough assessment of fluorescent uptake
throughout whole cells, all images were captured as a series of
slices in the Z plane (range 3–10 slices per area selected, each
slice 0.54µmapart) with the 40x objective using live cell spinning
disk confocal microscopy (Andor Revolution XD coupled to an
Olympus IX-81 inverted microscope; Andor Belfast UK). All
images were digitally recorded with IQ2 software (Andor, Belfast,
UK).
Cell Stimulation Experiments for
Subsequent Protein or mRNA Extraction
Primary human myometrial cells at passage ≤ P4 were split
equally between 6 or 12 well-plates and grown to 80–90%
confluency. At this point media was changed to serum-reduced
(0.1% FCS) media for 18 to 24 h before discarding from each
well. Five hundred microliters of fresh media (0.1% FCS) was
produced containing: Pen-NBD, Pen(43-56)-NBD, Sc514 (Tocris
bioscience, 3318); or controls (equivalent volume DMSO, Pen-
NBD Mutant, NBD alone) at indicated concentrations. The
inhibitor/control media was added to wells as a pre-incubation
step. After 1 h, 10 ng/ml IL1β (Peprotech, 200-01B), or equivalent
volume DMSO vehicle, was added to each well.
For western blotting experiments cells were washed with
PBS before being lysed using sucrose cell lysis buffer (62.5mM
Tris-HCl pH6.8, 2% SDS, 10% saccharose) containing 20
µl/ml protease inhibitor (Sigma Aldrich, P1860) and 5 µl/ml
phosphatase inhibitor (Sigma Aldrich P2745) at times of
0/15/60/120/240 minute from cytokine stimulation.
For RNA array experiments, 4 h following cytokine
stimulation cells were washed with PBS before RNA was
extracted using the RNeasy Mini Kit (Qiagen, 74101) according
to the manufacturers’ protocol.
Western Immunoblotting
Cell lysate samples were sonicated and underwent Lowry assay
to determine overall protein concentration before dilution in an
equal volume of 2x Laemmli buffer (Tris pH6.8 250 nM; SDS 4%
w/v; Glycerol 10% v/v; β-mercaptoethanol; bromophenol blue).
Ten micrograms of sample protein per lane was loaded onto a
1.5mm 10% sodium dodecyl sulfate poly-acrylamide gel (SDS-
PAGE) before undergoing separation by electrophoresis, gels
then underwent electrophoretic transfer to a methanol-activated
polyvinylidine difluoride (PVDF) membrane.
Following a blocking step of washing membranes in 5%
non-fat dry milk in Tris-buffered saline with 0.1% Tween-
20 (TBS-T) for 1 h at room temperature, membranes were
incubated overnight at 4◦C with primary anti-COX-2 antibody
1:500 (Cayman laboratories, CAY160112), anti-IκB-α antibody
1:500 (Santa Cruz, C21 Sc371) anti-phospho-P65 antibody
1:2000 (Cell Signaling, 3013), or anti-P65 antibody 1:15,000
(Santa Cruz, Sc372) in 1% non-fat dry milk with TBS-T. After
three washing steps with TBS-T, secondary antibody incubation
occurred for 1 h at room temperature. Polyclonal horseradish
peroxidise conjugated goat anti-mouse immunoglobulin 1:3000
(DAKO, P0447) in 1% non-fat dry milk was used in conjunction
with COX2 antibody and a polyclonal horseradish peroxidise
conjugated goat anti-rabbit immunoglobulin 1:5000 in 1% non-
fat dry milk (DAKO, P0448) was used for IκB-α, phospho-P65
and P65 antibody.
After further TBS-T wash, enhanced chemiluminescent
(ECL) reagent (Fisher Scientific, 12316992) was applied to
the PVDF membranes for 5min. Membranes were dried,
placed in development cassettes and developed manually onto
photographic film in a dark room. Equal loading of proteins
was assessed by staining of the PVDF membrane with Napthol
Blue Black Reagent (0.1% napthol blue black, 10% methanol,
2% acetic acid) to detect actin protein (43kDa). Developed
films were densitometrically scanned using UMAX PowerLook
III (UMAX) and quantification performed with Bio Image
Intelligent Quantifier 2 software (Bioimage systems).
Measurement of mRNA Expression
Following extraction of RNA (as per above), gene expression
was assessed via the measurement of mRNA transcripts across
a panel of selected genes using RT qPCR arrays (Qiagen, Custom
RT2 profiler PCR arrays, 330171). All work was carried out in a
ribonuclease free environment with ribonuclease free equipment.
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TABLE 2 | Genes used in RT2 profiler PCR array plates.
Gene grouping Gene name
Labor associated genes OXTR/MMP 9/ MMP19/ TIMP1/ GJA1/GJB2
Inflammatory Genes IL1A/IL1B/TNFA/IL6/IL8/ICAM1/ SOCS3 /IL1R1/
IL1R2/IL4R/CXCL2/ CXCL1/CXCL6/CCL2
NFκB pathway NFKB1/NFKB2/ RELA/NFKBIA/NFKBIZ
Prostaglandin production PTGER3/PLA2G2A/ PTGES/PTGS2
G protein receptors GPR37/GPR34/RGS 10
Novel genes S100A9/ S100A8/STAT1/ FOXO1/ ZEB1/ LILRA5/
SPINK5/FOSB/JUN/TRIB1
Housekeeping genes GAPDH/ACTB/B2M
Measurement of the RNA content in each sample was undertaken
using a nanodrop spectrophotometer (ND-1000, Labtech), with
suitable RNA purity considered to be a 260/280 ratio of >2.1.
0.5 µg of total RNA from each sample was added to the
genomic DNA elimination mix from RT2 first strand kit (Qiagen,
330404) reverse transcription was then carried out according the
manufacturers’ instructions.
cDNA as synthesized from 0.5 µg of total RNA from each
original sample was added to the SYBR Green Master Mix
(Qiagen, 330171). Twenty-five microliters of this final mix was
then added to each well of a 96 well-array plate, with each well-
containing a different primer for a gene of interest or control.
The plate was sealed with optical film, centrifuged at 1,000 rpm
(89 × g) for 1min before inserting the plate into the PCR cycler
(Step One Plus, Applied Biosciences) according to a protocol of
enzyme activation hot start at 95◦C for 10min, followed by 40
cycles of denaturing at 95◦C for 15 s and extension at 60◦C for
60 s.
Fluorogenic data was collected via the FAM channel and
the cycle threshold (Ct) values were calculated by applying
a threshold limit that represented the exponential phase of
amplification. To ensure comparability of gene expression
between different array plates the same threshold limit was
applied to all experiments (Ct 0.116). This was calculated as a
mean threshold value from the first 6 arrays and corresponded
to the exponential phase of the amplification curve for all
subsequent experiments.
These array plates were created bespoke for the authors by
Qiagen and the genes selected for examination are demonstrated
in Table 2. The approach taken to gene selection is described
within the results section below.
Analysis of mean Ct values and quality control were evaluated
by exporting mean Ct values for each gene on the RT2 array
plate to the following data analysis website supported by Qiagen:
https://dataanalysis.sabiosciences.com/pcr/arrayanalysis.php.
Gene expression was normalized to three reference
housekeeping genes β2-microglobulin (B2M), GAPDH and
ACTB, and results calculated using the11CT method.
For all qPCR gene array experiments raw Ct values are
included in the Supplemental Data 1.
Statistical Analysis
Prism 7.0 (GraphPad) software was used to perform statistical
analysis. For western blotting data statistical analysis was
performed on raw optical densitometry values. One or two-
way (time/dose) ANOVA with post-hoc corrections were
performed to compare differences between groups, as indicated
in figure legends. For initial mRNA expression experiments
comparing untreated and IL1β treated samples (Figure 8)
P-values were calculated based on a Student’s t-test of
the replicate 2∧11Ct values of each gene. For subsequent
mRNA experiments comparing inhibitor groups (Table 3 and
Supplemental Figure 3) one-way ANOVA with Bonferroni post-
hoc corrections were performed to compare differences between
groups. Statistical significance was assumed at P < 0.05.
For all experimental conditions: each n represents a biological
replicate i.e., each n is a separate experiment using cell cultures
grown from myometrial biopsy of a new patient.
RESULTS
Penetratin CPP Effectively Delivers
Fluorescent Cargo to Human Myometrial
Cells
Using the well-characterized Penetratin CPP, we initially
investigated whether human myometrial cells were accessible to
the CPP-mediated delivery of rhodamine fluorophore.
Figure 1 displays representative confocal microscope images
of live uterine smooth muscle cells 1 h after application of
rhodamine fluorescent cargo conjugated to either Penetratin
(CPP), Pen-NBD, or to Pen(43-56)-NBD. The delivery of
fluorescent cargo was assessed by comparison to that of a
rhodamine-conjugated control peptide purported to not have
cell penetrating ability [GS4 (GC)] (40) which can be viewed in
Figure 1D.
At 1, 3, and 10µM the rhodamine fluorophore was
successfully delivered internal to the cells within 60min of
application, with an increase in intensity of uptake with
increasing concentration (Figures 1A–C). By comparison the
inert peptide GS4 (GC) at 10µM did not appreciably deliver the
rhodamine fluorophore after 60min (Figure 1D). This indicates
the ability of CPPs to deliver cargo to human myometrial cells.
Following 60min of cellular application, the CPP-fluorophore
conjugates (Figure 1A) and also the CPP-cargo-fluorophore
conjugates (Figures 1B,C) largely demonstrated a punctate
pattern of labeling indicative of endosomic labeling. This is best
demonstrated in the image of Rhodamine-Pen-NBD at 10µM
(Row B, third picture from left). It can be noted that this punctate
labeling forms larger accumulations with the use of Pen(43-56)-
NBD (Figure 1C), this may be attributed to alteration of the
CPP-cargo amino acid structure, a phenomenon referred to in
the discussion below.
The CPP-Cargo Conjugate Pen-NBD
Inhibits Cytokine-Activated COX2
Expression
Initial experiments determined that CPP use was not
toxic to myometrial cells (Supplementary Figure 4).
Penetratin conjugated to the NBD peptide (Pen-NBD) was
applied to myometrial cell cultures in increasing concentrations
1 h prior to addition of 10 ng/ml of IL1β. As demonstrated
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FIGURE 1 | Confocal microscopy images of live human uterine smooth muscle cells following application of rhodamine-conjugated CPPs or CPP-cargo
combinations. Images captured 60min following addition of either 1, 3, or 10µM concentrations of (A) Rhodamine—Penetratin, (B) Rhodamine—Pen-NBD, or (C)
Rhodamine—Pen (43-56)-NBD. (D) Displays cells imaged 60min following addition of 10µM control peptide Rhodamine - GS4 (GC). Scale bars 20µm. Cells are
maintained in serum deprived media within a temperature-controlled chamber (37◦C, 5%CO2). To demonstrate intra-cellularity of uptake, images are taken from the
center of a Z-stack of 3–10 slices (0.54µm apart) intended to capture the full depth of the cell. Images are representative of 3 independent experiments.
in the Western blot portrayed in Figure 2: in the absence of
inhibitor (IL1β alone) induction of the protein enzyme COX2 is
evident at 2 h and continues to increase at 4 h following cytokine
application. Pre-incubation of 50 and 100µM Pen-NBD led
to significant inhibition of these cytokine-stimulated increases
in COX2 protein signal at both 2 h (50µM p = 0.01; 100µM
p= 0.003) and 4 h (50µM p= 0.049; 100µM p= 0.0003).
Control experiments were performed to test the specificity
of COX2 responses to the NBD peptide. The inhibitory effect
of Pen-NBD on IL1β-induced COX2 protein expression was
compared with a Penetratin-conjugated mutant version of the
NBD peptide: Pen-NBD (Mut), and NBD peptide alone (without
conjugation to CPP). Figure 3 displays a representative Western
blot with scatter graphs demonstrating three independent
experiments to compare COX2 protein responses to IL1β
following the pre-incubation with either Pen-NBD mutant or
wild type peptide. It demonstrates that the mutant peptide does
not diminish IL1β-stimulated COX2 induction when used at
identical concentrations to the wild type peptide.
Application of non-conjugated NBD peptide had no
inhibitory effect on cytokine-stimulated COX2 protein increases,
nor did application of CPP alone (Supplementary Figure 1),
thus indicating the requirement of CPP-conjugation to NBD for
the inhibitory effect to be evident.
In Human Myometrial Cells Pen-NBD Does
Not Prevent the Cytokine-Stimulated
Degradation of IκBα but Does Diminish
Phosphorylation of P65 Following IL1β
Exposure
It was important to assess the effect of CPP-based inhibition
on protein expression changes within the canonical NFκB
pathway subsequent to IL1β stimulation. Within myometrial
cells, increases in the phosphorylated form of the NFκB subunit
p65 protein are observed at 15min due to the action of
the activated IKK complex (Supplementary Figure 2), these
responses gradually diminish over the tested 4 h time frame but
do not return to normal, suggestive of increased background
NFκB activity following cytokine stimulation in human uterine
cells over the time frame examined. Additionally, within 15min
of exposure to IL1β, there is both phosphorylation of the
inhibitory IκBα protein and degradation of its native form with
full return of the native form of this inhibitory protein occurring
between 60min and 2 h.
At all concentrations tested, Pen-NBD did not
prevent the cytokine-induced degradation of IκBα
(Figure 4A). However, a significant reduction of P65 protein
phosphorylation 15min following application of IL1β was
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FIGURE 2 | Effect of Pen-NBD peptide on IL1β-stimulated COX2 protein increases. (Upper) Representative Western blot demonstrating COX2 protein increase at 2
and 4 h following application of 10 ng/ml IL1β alone or with pre-incubation for 1 h with indicated concentrations of Pen-NBD peptide prior to IL1β addition. Actin
expression displayed as loading control. Ø= no protein loaded. (Lower) Scatter plot demonstrating optical density values of COX2 protein signal at 2 and 4 h time
points comparing IL1β alone or Pen-NBD plus IL1β experiments. Data presented has been normalized to control signal to demonstrate inhibitory effect. *Significant
difference from raw optical density values between IL1β alone and IL1β plus Pen-NBD groups (n = 4, one-way ANOVA with Bonferroni post-hoc correction).
observed with the use of 100µM Pen-NBD (p = 0.025)
(Figure 4B).
The NBD Peptide Conjugated to the
Truncated Penetratin Vector Pen(43-56) Is
Capable of COX2 Inhibition but Is Less
Efficacious Than Pen-NBD and Does Not
Influence IKK-Dependent Protein
Alterations Within the NFκB Pathway
To test the effect of alterations of the CPP vector on the efficacy
of NBD cargo protein-protein interactions, experiments were
performed using the NBD peptide conjugated to a truncated
arrangement of the CPP Penetratin, to form Pen(43-56)-NBD.
This CPP-peptide fusion has previously demonstrated ability
to block IL1β-induced NFκB activity in HeLa cell lines (38),
but has not been examined previously in a gestational cell
setting.
Applied to human myometrial cells 100µM Pen (43-56)-
NBD was able to inhibit IL1B-induced COX2 protein increases
at 4 h (p = 0.0045) (Figure 5A). Such inhibition was not seen
with the use of lower doses (data not shown). This CPP-cargo
conjugation did not inhibit IκBα protein degradation or P65
protein phosphorylation (Figures 5B,C).
The Small Molecule Inhibitor Sc514 Exerts
Inhibitory Effect on COX2 Protein Induction
Via Alteration of IKK-Dependent Events
Within the NFκB Pathway
Sc514 at 50µMconcentration was applied tomyometrial cells 1 h
prior to IL1β stimulation. Significant reduction in COX2 protein
expression with the use of this inhibitor was observed at 4 h
(p = 0.001). IL1β -induced degradation of IκBα was inhibited
(p= 0.009) as was the phosphorylation of P65 protein (p= 0.001)
(Figures 6A–C).
IL1β Promotes Inflammation- and
Labor-Related Gene Expression Changes
in Human Myometrial Cells
To further demonstrate the response of myometrial cells to
inflammatory stimulation and to compare the ability of CPP
based and small molecule inhibitory strategies to these responses
a bespoke q-PCR array panel of 42 genes was used. The genes
examined in this study are listed in Table 2. The approach to
gene selection for this panel was multifactorial: a number of
genes encoding for proteins associated with the physiological
events of uterine contraction, cervical dilation and membrane
rupture that occur during human labor, termed labor associated
genes, were selected (41); also, for comparison, a collection of
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genes encoding for G-proteins involved in maintaining uterine
quiescence (42). A number of pro inflammatory genes, including
genes encoding for proteins in the NFκB pathway (16), and genes
involved in the production of prostaglandins (18) were chosen
to aid understanding of the potential mechanism of action of
inhibitors used in this study. A selection of novel genes that
demonstrate altered expression in the presence of human labor
were also included in the array (43).
Across eight independent samples a series of gene expression
changes were observed inmyometrial cells 4 h following exposure
to 10 ng/ml IL1β. These changes included genes involved in
human labor, inflammatory processes, NFκB signaling, and
prostaglandin expression as demonstrated in the heat map
displayed in Figure 7.
The volcano plot presented in Figure 8 demonstrates those
genes exhibiting significant expression changes with greater than
2-fold difference between IL1β-treated and untreated samples.
The genes displaying the largest expression changes within
the panel were inflammatory cytokines/chemokines and genes
associated with the NFκB family.
FIGURE 3 | Comparison of effect of Pen-NBD mutant (Mut) peptide with
Pen-NBD wild type (WT) on IL1β-stimulated COX2 protein responses. (A)
Representative Western blot demonstrating COX2 protein changes at
indicated time points. Lanes 1,2,8, and 9 display protein expression with no
agonist addition. Lanes 3 and 10 display protein expression with addition of
10 ng/ml IL1β alone. Lanes 4 and 11 display protein expression with DMSO
vehicle plus IL1β. Lanes 5 and 6 display protein expression with Pen-NBD
(Mut) at indicated concentrations plus IL1β and lanes 12 and 13 display
Pen-NBD (WT) at indicated concentrations plus IL1β. Actin expression
displayed as loading control. Lane 7—no protein addition. (B) Scatter plots
demonstrating comparison of optical density values of COX2 protein signal
between IL1β only, IL1β plus Pen-NBD (Mut), or IL1β plus Pen-NBD (WT) at
indicated concentrations. *Significant difference from raw optical density
values between IL1β only and IL1β plus Pen-NBD groups (n = 3, one-way
ANOVA with Bonferroni’s post-hoc correction).
CPP-Conjugated and Small Molecule
Inhibitors of NFκB Dampen the
IL1β-Stimulated Expression of Different
Groups of Genes in Myometrial Cells
Having identified expression changes within the gene array panel
following stimulation by IL1β, it was important to examine how
this expression pattern would be altered using a CPP-based or
small molecule inhibitory strategy. It was also of interest to
observe how alterations to vector structure may affect the efficacy
of CPP-cargo inhibition.
Application of either Pen-NBD, Pen(43-56)-NBD or
Sc514, 1 h prior to cytokine exposure, significantly inhibited
the IL1β-stimulated expression of many genes within the
array panel. The pattern of inhibition can be observed in
both Table 3 and the scatter graphs demonstrating fold
expression changes presented within the Supplementary Data
(Supplementary Figures 3A–E).
Of note, Pen-NBD and Sc514 had broad and similar anti-
inflammatory effects and both approaches significantly inhibited
NFκB family gene expression and prostaglandin pathway
expression. For the labor associated genes: Pen-NBD, but not
Sc514, inhibited the cytokine-induced expression of the oxytocin
TABLE 3 | Effect of CPP-based or small molecule inhibitors on IL1β induced gene
expression changes in myometrial cells.
Gene group Gene name Inhibitor
Pen-NBD Pen(43-56)-NBD Sc514
Labor
associated
genes
OXTR ↓ (p = 0.01) – –
MMP9 – – ↓ (p = 0.01)
Inflammatory
cytokines
IL1A ↓(p ≤ 0.0001) ↓(p = 0.003) ↓(p = 0.001)
IL1B ↓(p ≤ 0.0001) ↓(p = 0.034) ↓(p = 0.004)
TNF – – ↓(p = 0.0004)
IL16 ↓(p = 0.016) – ↓(p = 0.0004)
IL18 ↓(p = 0.023) – ↓(p = 0.0007)
ICAM1 – – ↓(p = 0.04)
Inflammatory
chemokines
CXCL2 – – ↓ (p = 0.0013)
CXCL6 ↓(p ≤ 0.0001) ↓(p ≤ 0.0001) -
CCL2 ↓(p ≤ 0.0001) ↓(p = 0.0003) ↓(p = 0.01)
NFκB family
genes
NFKB1 ↓(p = 0.0039) – ↓(p = 0.001)
NFKB2 ↓(p = 0.01) – ↓(p = 0.045)
RELA ↓(p = 0.0049) – -
NFKBIZ – – ↓ (p = 0.008)
Prostaglandin
pathway
genes
PTGES ↓(p ≤ 0.0001) ↓(p = 0.003) –
COX2 ↓ (p = 0.0007) – ↓(p = 0.01)
Taken from the 42 gene array, the table demonstrates only the genes with significantly
altered expression patterns between control (IL1β alone) or treatment (IL1β plus
either 100µM Pen-NBD/100µM Pen(43-56)-NBD/50µM Sc514) groups. ↓ indicates
significantly altered gene expression in presence of inhibitor compared with IL1β alone. –
indicates no significant change between groups. Scatter graphs demonstrating changes
for each gene displayed can be found in Supplementary Figure 3.
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FIGURE 4 | Effect of Pen-NBD on the cytokine–induced degradation of IκBα protein and phosphorylation of P65 protein. (Left) Representative Western blots
demonstrating responses of (A) IκBα protein and (B) phosphorylated P65 protein at 15 and 60min following application of 10 ng/ml IL1β either alone or following
pre-incubation for 1 h with indicated concentration of Pen-NBD peptide prior to IL1β addition. Actin expression displayed as loading control. Ø= no protein loaded.
(Right) Scatter plots demonstrating raw optical density values of (A) IκBα protein and (B) phosphorylated P65 protein signal at 15 and 60min time points comparing
IL1β alone or 100µM Pen-NBD plus IL1β experiments. *Significant difference from raw optical density values between IL1β alone or 100µM Pen-NBD plus IL1β
groups (n = 4, two-way ANOVA with Sidak’s post-hoc correction).
receptor gene OXTR. In contrast, Sc514, but not Pen-NBD
inhibited the gene encoding for the matrix metalloproteinase
MMP 9.
Use of the truncated CPP vector Pen (43-56) combined with
NBD demonstrated muchmore limited ability to inhibit cytokine
induced changes in gene expression and did not affect the
expression of NFκB pathway, prostaglandin, or labor associated
genes. This further demonstrates the importance of appropriate
vector selection for any treatment strategy involving CPP-Cargo
delivery.
DISCUSSION
Within the reproductive literature a substantial body of evidence
places intracellular NFκB activation centrally amongst the
molecular pathways associated with inflammatory preterm birth
(12, 44). With this in mind, a novel approach was adopted here
to investigate inhibition of inflammatory signaling in human
myometrial cells. We compared two classes of agent targeting
the IKK complex upstream within the NFκB pathway, aiming to
diminish NFκB-dependent uterine cell inflammatory responses:
CPP’s conjugated to the NBD peptide and the small molecule
inhibitor Sc514.
The CPP-cargo construct, Pen-NBD, was used with the aim
of avoiding the need for receptor-ligand interactions on the
cellular membrane and thus to precisely deliver bioactive cargo
to the intended intracellular target. COX2 is an inducible rate-
limiting enzyme in the production of prostaglandins in uterine
cells. Prostaglandins are vital mediators in the induction of
laboring processes and potent uterotonins that can initiate
uterine contractions therefore the demonstration in this study
that CPPmediated delivery of the NBD peptide inhibits the IL1β-
induced expression of COX2 is of importance. A previous study
examining the effect of the NBD peptide in a sheep model found
it to be broadly ineffective at dampening inflammatory responses
in sheep fetal membranes at 10µM (45). This work supports
that conclusion, but also emphasizes the importance of basic
testing of novel compounds over a broad time and concentration
range as inhibition of inflammatory responses was only observed
at concentrations greater than or equal to 50µM within the
experiments presented here.
Hundreds of CPP sequences have now been discovered that
could be linked to the NBD peptide. Even amongst well-
characterized CPPs such as Penetratin or TAT differences exist
within the literature as to the precise amino acid structure used
(46), and differences in the position of key amino acid residues
or charged groups within the CPP vector-cargo conjugate can
alter the efficiency of delivery, with the possibility that this may in
turn affect the biological effectiveness and targeting of the peptide
(47, 48). In order to explore this effect of vector alteration on
the overall efficacy of CPP-cargo combination, this study also
examined NBD delivery and biological effect when combined
to a truncated form of Penetratin CPP (Pen 43–56) that has
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FIGURE 5 | Effect of Pen (43-56)-NBD on cytokine-induced alterations of (A)
COX2, (B) IκBα, and (C) phosphorylated-P65 proteins. (Left) representative
Western blots demonstrating protein responses at indicated time points
following application of 10 ng/ml IL1β either alone or following pre-incubation
for 1 h with 100µM of Pen(43-56)-NBD peptide prior to IL1β addition. Actin
expression displayed beneath as loading control. (Right) Scatter plots
demonstrating protein signal raw optical density values comparing IL1β alone
or 100µM Pen-NBD plus IL1β experiments.*Significant difference from raw
optical density values between IL1β alone or 100µM Pen-NBD plus IL1β
groups (n = 3–4, one-way ANOVA with Bonferroni’s post-hoc correction).
two lysine amino acid residues removed from the C-terminal
end of the peptide (49). Conjugated to rhodamine Pen(43-56)–
NBD demonstrated ability to enter myometrial cells within a
similar time-dose range to Pen-NBD, but it was notable that
the intracellular appearances of fluorophore were larger, possibly
due to a clumping phenomenon secondary to altered charge and
pH properties of the truncated CPP-cargo construct. Pen(43-56)-
NBD also required increased concentrations to inhibit cytokine-
induced increases in COX2 protein when compared to the non-
truncated form and did not prevent alterations of NFκB pathway
proteins downstream of IKK complex activation. Additionally,
pen(53-46)–NBD was less effective in attenuating IL1β-induced
gene expression changes compared with Pen-NBD peptide. Thus,
careful selection of the CPP vector used, consideration of vector-
cargo interactions and investigation of mechanisms of action are
vital considerations for work involving peptide-based therapies.
The small molecule inhibitor Sc514 was chosen to compare
this CPP-based therapeutic approach as it has a putatively very
similar mechanism of action focussed on interaction with IKK
FIGURE 6 | Effect of Sc514 on cytokine-induced alterations of (A) COX2, (B)
IκBα, and (C) phosphorylated-P65 proteins. (Left) representative Western blots
demonstrating protein responses at indicated time points following application
of 10 ng/ml IL1β either alone or following pre-incubation for 1 h with 50µM
Sc514 prior to IL1β addition. Actin expression displayed beneath as loading
control (n = 3 COX2/IκBα, n = 5 p-P65,). (Right) scatter plots demonstrating
protein signal raw optical density values comparing IL1β alone or 50µM
Sc514 plus IL1β experiments. *Significant difference from raw optical density
values between IL1β alone or 50µM Sc514 plus IL1β groups (n = 3
COX2/IκBα, n = 5 p-P65 two-way ANOVA with Sidak’s post-hoc correction).
complex to prevent its activation within the canonical NFκB
pathway. As with Pen-NBD, Sc514 demonstrated ability to inhibit
cytokine-induced COX2 production and p65 phosphorylation.
However, whereas Pen-NBD did not prevent the IL1β-dependent
degradation of IκBα, Sc514 demonstrated ability to inhibit
degradation of this protein. Therefore, the ability of Sc514
to prevent the degradation of this protein in comparison to
the NBD cargo may relate to subtle differences in mechanism
of action. The IKKβ subunit is primarily responsible for the
phosphorylation of IκBα from which subsequent degradation
occurs and Sc514 has previously demonstrated specificity toward
IKKβ inhibition (35), whereas NBD peptide blocks association
between NEMO and the other subunit portions of the IKK
complex (29). Thus, the inability of Pen-NBD to prevent IκBα
degradation in myometrial cells could either be due to an
incapacity to dampen IKKβ-specific responses or to the actions
of alternative IKK complexes within the cell that can lack Nemo
Binding Domain (50).
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FIGURE 7 | Heat map demonstrating myometrial cell gene array expression in
response to IL1β cytokine stimulation. The heat map displays gene expression
changes from an array of 42 GOI for untreated and IL1β treated samples from
eight biological replicates. Highly expressed genes are displayed as shades of
red and minimally expressed genes are shown as shades of green (n = 8).
To examine the wider anti-inflammatory effects of both CPP-
cargo and small molecular inhibitory approaches the expression
of a bespoke array of genes was used to examine myometrial
gene expression changes in response to cytokine stimulation,
and, subsequently, the effect of the inhibitory approaches to
dampen such responses. Application of IL1β to myometrial
cells produced many gene expression changes that have been
previously observed in comparisons between human laboring
and non-laboring samples including upregulation of NFκB
pathway components, cytokines such as IL6 and IL8 and genes
with specific associations with human labor such as PTGS2 and
OXTR (51, 52).
Sc514 and Pen-NBD had similar anti-inflammatory effects
dampening the cytokine-provoked transcription of NFκB family
genes and key cytokines such as IL6 and IL8. There were
interesting variations in this effect with Pen-NBD demonstrating
inhibition of OXTR, the gene transcribing for oxytocin
receptor protein; whereas Sc514 inhibited the cytokine-induced
upregulation of the matrix metalloproteinase enzyme gene MMP
9. Such variations suggest that with future work to clarify the
detailed mechanistic processes behind the varied presentations
of preterm birth, different inhibitory approaches could be taken
dependent on individual biological situations. It also gives rise
to the possibility that in situations where a broad insult is
responsible for the onset of preterm birth, more than one agent
may be required to prevent this outcome.
LIMITATIONS
A consistent limitation of fundamental biological studies
investigating several outcomes of multiple interventions when
using primary sourced human material is tissue availability. This
can be further exacerbated when studies refrain from using
cells at high passage (>4) to minimize potential deviation from
original cellular phenotype. Within such practical and temporal
constraints, the final numbers used in some experiments within
this study are low; however, the authors feel this does not detract
from the innovative nature of the study, and offers incentive for
more detailed investigation of the uses of CPP based therapies
and Sc514 as inflammatory and potentially contractile inhibitors
for use in the field of pregnancy research.
CONCLUSION
Due to the shortage of candidate agents aimed at the prevention
of preterm birth available for clinical testing, a number
of approaches have been investigated with the intention of
dampening inflammatory-mediated signaling in uterine cells (53,
54). However, most of these, outside of anti-infection strategies,
rely upon inhibiting plasmalemmal receptor engagement with
cognate ligands. This study presents a novel approach to
addressing this problem by establishing that a biologically
active cargo, intracellularly delivered by a CPP, can inhibit
inflammation-related signaling in human myometrial cells in
a similar manner to that of the potent cell-permeable small
molecule inhibitor Sc514.
CPPs have the potential to deliver a diverse range of cargo to
cells thus the proof of concept demonstrated here that CPP-cargo
constructs enter human uterine smooth muscle cells and dampen
inflammatory pathways in a targeted fashion is encouraging
for the further pursuit of strategies involving varied CPP-cargo
constructs that could include targeting alternative inflammatory
pathways associated with preterm birth such as MAP kinase
and AP1 (10, 11). It is well-established that many protein-
protein interactions are classed as non-druggable and cannot be
inhibited with small molecule drugs or large proteins and this
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FIGURE 8 | Volcano plot demonstrating gene expression changes in myometrial cells following IL1β exposure. X axis shows fold regulation changes between IL1β
treated and untreated samples 4 h following cytokine addition. Y axis is the inverse of the p value generated for each gene of interest (GOI) via students T-test. All
genes with >2 fold difference between IL1β treated and untreated samples are labeled on the figure. Upregulated genes are presented as red circles, downregulated
genes are green circles and genes demonstrating no change are black circles. Genes above the blue horizontal line represent significant expression changes between
IL1β and untreated samples (Student’s t-test of the replicate 2∧11Ct values). Data is summation of experiments from eight biological replicates (n = 8).
offers an opportunity for investigating more peptide therapeutics
delivered by CPPs.
Although further extensive preclinical testing of these
therapeutic strategies is required to establish safety and efficacy
over a broad concentration range; the authors envisage the future
usage of such agents in an acute setting for pregnant patients
presenting with the clinical phenotype of regular contractions
before 37 weeks of completed gestation with the intention of
both delaying birth to reduce the impact of prematurity on
the fetus, and ameliorating the effect of inflammatory insult
to both mother and fetus. Treatment delivery could be either
through local application to gestational tissues via vaginal
pessary; or techniques are evolving quickly for tissue and/or
cell-specific delivery of biologically active mediators, including
those directed toward uteroplacental environments (55, 56),
enabling the consideration of systemic usage. Thus, there is much
promise for extending in the near future the use of Pen-NBD,
other CPP-cargo conjugates and Sc514 to preclinical models of
preterm birth.
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